Business
Intellia's Crispr Experimental Gene-editing Therapy Cut Levels of an Abnormal Liver ... - Latest Tweet by Bloomberg
The latest Tweet by Bloomberg states, 'Intellia’s Crispr experimental gene-editing therapy cut levels of an abnormal liver protein in interim, early-stage trial results ...'
Intellia’s Crispr experimental gene-editing therapy cut levels of an abnormal liver protein in interim, early-stage trial results https://t.co/p2Fl7ssI5v— Bloomberg (@business) February 28, 2022
(The above story first appeared on LatestLY on Mar 01, 2022 03:48 AM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).
